Rosiglitazone Inhibits Adrenocortical Cancer Cell Proliferation by Interfering with the IGF-IR Intracellular Signaling
Figure 1
Adrenocortical cancer is
responsive to IGFs. (a) Western blot analysis of adrenocortical tissues
(adrenocortical carcinoma: ACC; normal adrenal tissue: NOR; adrenocortical
adenoma: ADE) and adrenocortical cancer cell lines (SW13 and H295R) reveals a
high expression of IGF-IR in cancer tissue and cells and lower levels in normal
and adenoma tissues. Western blot for actin was performed for lane protein normalization.
Molecular weight (Mw) markers are indicated. The effects of cell incubation
with increasing doses of IGF-I (1, 10 and 50 nM) for the indicated times on
cell proliferation were evaluated by MTS in SW13 (b) and H295R (c) and
confirmed in H295R by evaluation of [3H]TdR incorporation in cell
DNA content (d). Data represent mean SE OD (b), (c) or mean SE of [3H]TdR
incorporation (counts per minute, cpm) (d). Statistical significance versus
respective control: , °, §, #.
